Drugs / ACE-232
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06801236 | May 2025 → Mar 2028 expected | castration-resistant prostate carcinoma, prostate adenocarcinoma | Acerand Therapeutics (Hong Kong) Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-07-22 | Acerand Therapeutics (Shanghai) Limited | Regulatory Acerand Therapeutics gets the greenlight by CDE for the clinical study of ACE-232 (a novel CYP11A1 inhibitor ) in China acerand.com ↗
Acerand Therapeutics is pleased to announce that Acerand gets Center for Drug Evaluation (CDE) greenlight today for the open-label, multi-center Phase I study of ACE-232 (a novel CYP11A1 inhibitor) in China. |
| 2025-04-10 | Acerand Therapeutics (Shanghai) Limited | Results Acerand Announces Promising ACE-232 Preclinical Data to Be Presented at the 2025 AACR Meeting acerand.com ↗
Acerand, a biopharmaceutical company focused on developing innovative therapies, today announced compelling preclinical data for its novel and highly selective CYP11A1 inhibitor, ACE-232. |
| 2025-01-17 | Acerand Therapeutics (Shanghai) Limited | Regulatory Acerand Therapeutics announced the approval of their novel CYP11A1 inhibitor ACE-232 by FDA for clinic investigations acerand.com ↗
Acerand Therapeutics is pleased to announce that on January 10 of 2025, the U.S. Food and Drug Administration (FDA) granted approval for the first-in-human, open-label, multi-center Phase I study of its novel CYP11A1 inhibitor, ACE-232. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-22 | Acerand Therapeutics (Shanghai) Limited | Acerand Therapeutics gets the greenlight by CDE for the clinical study of ACE-232 (a novel CYP11A1 inhibitor ) in China acerand.com ↗ |
| 2025-06-04 | Acerand Therapeutics (Shanghai) Limited | Acerand Therapeutics Initiates First-in-Human Phase 1 Clinical Trial of ACE-232, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer acerand.com ↗ |
| 2025-04-10 | Acerand Therapeutics (Shanghai) Limited | Acerand Announces Promising ACE-232 Preclinical Data to Be Presented at the 2025 AACR Meeting acerand.com ↗ |
| 2025-01-17 | Acerand Therapeutics (Shanghai) Limited | Acerand Therapeutics announced the approval of their novel CYP11A1 inhibitor ACE-232 by FDA for clinic investigations acerand.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACE-232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06801236 ↗ |
| Known as | ACE-232 tablets | “ACE-232 tablets” NCT06801236 ↗ |
| Route | Oral | “ACE-232 tablets will be administered orally daily” NCT06801236 ↗ |